[Cardiac risks of adriamycin. Early detection of high-risk patients by isotopic cardiac function study].
Adriamycin is known to be effective in the treatment of breast cancer. Serial radionuclide determinations of the left ejection fraction can provide advanced warning of adriamycin cardiotoxicity, prior to clinical signs of the left ventricular dysfunction. Patients at high risk of congestive heart failure can be detected. Depending on the results of the second course of chemotherapy, guidelines and criteria can be laid down to predict the appropriate time for drug discontinuation.
D000328:Adult; D000368:Aged; D004317:Doxorubicin / Q000009:adverse effects*; D005260:Female; D006331:Heart Diseases / Q000139:chemically induced* / Q000503:physiopathology; D006334:Heart Function Tests / Q000379:methods*; D006801:Humans; D008875:Middle Aged; D012306:Risk; D013667:Technetium
D013667:Technetium; D004317:Doxorubicin
Risque cardiaque de l'adriamycine. Repérage précoce des sujets á haut risque par l'étude fonctionnelle cardiaque isotopique.